Trial Profile
Prospective One-center Open Label Observational Efficacy & Safety Study of Chlorambucil & Obinutuzumab in Treatment of Unfit Patients With Untreated Chronic Lympho Leukemia With Comorbidities
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Chlorambucil (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms GAIRI
- 14 Sep 2020 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 14 Sep 2020 Planned primary completion date changed from 31 Mar 2019 to 31 Aug 2024.
- 21 May 2018 New trial record